Microarray analysis as a prognostic and predictive tool: are we ready? Enzo Medico Laboratory of Functional Oncogenomics Institute for Cancer Research.

Slides:



Advertisements
Similar presentations
TOP2A IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN UNSELECTED BREAST CANCER Amit Pancholi Molecular Profiling of Breast Cancer: Predictive Markers of Long.
Advertisements

CD10, scored as positive versus negative all path 1 path 2 path 3 path 4 path 5 path 6 path 7 path 8 path 9 CD10 can be reproducibly scored, but is very.
Most Random Gene Expression Signatures are Significantly Associated with Breast Cancer Outcome Venet, et al. PLoS Computational Biology, 2011 Molly Carroll.
Molecular Systems Biology 3; Article number 140; doi: /msb
Is mammacarcinoom onder de veertig jaar morfologisch en genetisch een andere ziekte? Marc van de Vijver, Netherlands Cancer Institute, Amsterdam, NL.
The 70-Gene Profile and Chemotherapy Benefit in 1,600 Breast Cancer Patients Bender RA et al. ASCO 2009; Abstract 512. (Oral Presentation)
 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Biomarkers in Cancer (MBiC) slide presentation is not an independent.
Gene regulation in cancer 11/14/07. Overview The hallmark of cancer is uncontrolled cell proliferation. Oncogenes code for proteins that help to regulate.
MiRNA Platform Overview The Agilent miRNA Microarray System A New Microarray-based Tool for Profiling Human miRNAs.
Welcome to MATH:7450 (22M:305) Topological Data Analysis Office hours: MWF 15: :20 GMT (10: :20 CDT), M 2:00 - 3:00 am GMT (9pm - 10pm CDT)
Expression profiles for prognosis and prediction Laura J. Van ‘t Veer The Netherlands Cancer Institute, Amsterdam.
Microarrays Dr Peter Smooker,
Model and Variable Selections for Personalized Medicine Lu Tian (Northwestern University) Hajime Uno (Kitasato University) Tianxi Cai, Els Goetghebeur,
The Human Genome Project and ~ 100 other genome projects:
Microarray-based Disease Prognosis using Gene Annotation Signatures Michael Kovshilovsky Swapna Annavarapu SoCalBSI 2005.
Arrays: Narrower terms include bead arrays, bead based arrays, bioarrays, bioelectronic arrays, cDNA arrays, cell arrays, DNA arrays, gene arrays, gene.
Emergent Biology Through Integration and Mining Of Microarray Datasets Lance D. Miller GIS Microarray & Expression Genomics.
MammaPrint, the story of the 70-gene profile
References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.
Metastatic Breast Cancer: One Size Does Not Fit All Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service MSKCC.
Paola CASTAGNOLI Maria FOTI Microarrays. Applicazioni nella genomica funzionale e nel genotyping DIPARTIMENTO DI BIOTECNOLOGIE E BIOSCIENZE.
A comparative study of survival models for breast cancer prognostication based on microarray data: a single gene beat them all? B. Haibe-Kains, C. Desmedt,
Current concepts in Breast Cancer- Beyond TNM
About these slides SPEC – Short Presentation in Emerging Concepts Provided by the CAP as an aid to pathologists to facilitate discussion on the topic.
Predictive Biomarkers for Lung Cancer Current Status / Perspectives: Although curative resection of patients with early-stage lung CA are performed, the.
The 70 gene Mammaprint ™ signature: a comparison with traditional clinico-pathological parameters. Patrizia Querzoli 1, Massimo Pedriali 1, Gardenia Munerato.
A 14-gene prognosis signature predicts metastasis risk in node-negative, estrogen receptor-positive, Tamoxifen-treated breast cancer in different ethnogeographic.
Jo Anne Zujewski, MD Cancer Therapy Evaluation Program Division of Cancer Diagnosis and Treatment National Cancer Institute May 2011 Breast Cancer Biology.
Chapter 7 Essential Concepts in Molecular Pathology Companion site for Molecular Pathology Author: William B. Coleman and Gregory J. Tsongalis.
From motif search to gene expression analysis
Analysis of Molecular and Clinical Data at PolyomX Adrian Driga 1, Kathryn Graham 1, 2, Sambasivarao Damaraju 1, 2, Jennifer Listgarten 3, Russ Greiner.
The virochip (UCSF) is a spotted microarray. Hybridization of a clinical RNA (cDNA) sample can identify specific viral expression.
Enabling biomarker validation in breast cancer molecular subtypes: sensitivity and specificity of array-based subtype classification in 983 patients Balázs.
Exagen Diagnostics, Inc., all rights reserved Biomarker Discovery in Genomic Data with Partial Clinical Annotation Cole Harris, Noushin Ghaffari.
CDNA Microarrays MB206.
Gene-expression signatures for breast cancer prognosis, site of metastasis, and therapy resistance John Foekens Josephine Nefkens Institute Dept. Medical.
Supplemental Figures Loss of circadian clock gene expression is associated with tumor progression in breast cancer Cristina Cadenas 1*, Leonie van de Sandt.
Sgroi DC et al. Proc SABCS 2012;Abstract S1-9.
1 Decision tree based classifications of heterogeneous lung cancer data Student: Yi LI Supervisor: Associate Prof. Jiuyong Li Data: 15 th May 2009.
Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.
Scenario 6 Distinguishing different types of leukemia to target treatment.
Kelvin K. Tsai, M.D., Ph.D. Laboratory for Tumor Epigenetics and Stemness (TES Lab) NATIONAL INSTITUTE OF CANCER RESEARCH NATIONAL HEALTH RESEARCH INSTITUTES.
Doug Brutlag 2011 Genomics, Bioinformatics & Medicine Doug Brutlag Professor Emeritus of.
Gene Expression Signatures for Prognosis in NSCLC, Coupled with Signatures of Oncogenic Pathway Deregulation, Provide a Novel Approach for Selection of.
Techniques for Analysing Microarrays Which genes are involved in ovarian and prostate cancer?
Lecture 8. Functional Genomics: Gene Expression Profiling using DNA microarrays. Part II Clark EA, Golub TR, Lander ES, Hynes RO.(2000) Genomic analysis.
Idea: measure the amount of mRNA to see which genes are being expressed in (used by) the cell. Measuring protein might be more direct, but is currently.
Introduction to Microarrays Kellie J. Archer, Ph.D. Assistant Professor Department of Biostatistics
PREDICTING OUTCOME IN OSTEOSARCOMA USING A GENOME-WIDE APPROACH N Gokgoz,T Yan, M Ghert, S Eskandarian W He, R Parkes, SB Bull, RS Bell, IL Andrulis and.
Use of Oncotype Dx® Testing Breast SSG meeting 10 th July 2015 Dr Rebecca Bowen.
A comparative study of survival models for breast cancer prognostication based on microarray data: a single gene beat them all? B. Haibe-Kains, C. Desmedt,
Gene expression. Gene Expression 2 protein RNA DNA.
Case Study: Characterizing Diseased States from Expression/Regulation Data Tuck et al., BMC Bioinformatics, 2006.
Supplemental Table S1 Table S1. Quantitative real-time RT-PCR primer sequences for genes used in the publication. All sequences are listed in the 5’ –
A B C Supplementary Figure S1. Time-dependent assessment of grade, GGI and PAM50 in untreated patients Landmark analyses of the Kaplan-Meier estimates.
Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Gene Expression Signatures, Clinicopathological Features,
Annals of Oncology 23: 298–304, 2012 종양혈액내과 R4 김태영 / prof. 김시영.
G Mustacchi 1, F Zanconati 2, D Bonifacio 2, L Morandi 3, MP Sormani 4, A. Gennari 5, P Bruzzi 4 1: Centro Oncolgico University of Trieste 2: Inst of Pathology,
San Antonio Breast Cancer Symposium – December 6-10, 2016
Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.
Comparison between Pathologic Characteristics of Her2 Negative and Positive Breast Cancer in a Single Cancer Center in Jordan DR Majdi A. Al Soudi, MD,
Gene expression.
Deep Learning Analysis of Gene Expression Data for Breast Cancer Classification AS Y.P. Manawadu.
Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors  Anita Muthukaruppan, Annette Lasham,
Microarray Technology and Applications
High-level TNFSF13 predict a good response to post-operative chemotherapy in patients with basal-like breast cancer: A systematic review 林惠鈺1,2 歸家豪1,3.
A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer  Gen Wang, Xiaosong.
HER-2/neu mRNA detection by gene expression profiling
MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.
Highly metastatic PDAC cells have a unique gene signature, which is not preserved in metastases but predicts poor patient outcome. Highly metastatic PDAC.
Presentation transcript:

Microarray analysis as a prognostic and predictive tool: are we ready? Enzo Medico Laboratory of Functional Oncogenomics Institute for Cancer Research and Treatment University of Torino

Topics Platforms for gene expression profiling Breast cancer signatures From cell-based models to cancer classifiers

AFFYMETRIX GeneChip

45,000 gènes ! AFFYMETRIX GeneChip

The Probe Sets

Hybridization on the chip

Signal detection

Genomic raw data

Gene expression profiling by spotted microarrays Oligonucleotides or cDNAs Robotic printing

Gene expression profiling by spotted/dual colour microarrays RNA extraction, cDNA labelling Hybridization “Reference” RNA sample (pool)‏ “Test” sample (tumour specimen)‏

Different platforms generate different data types Two-colourOne-colour Paired samplesIndependent samples Ref vs Sample – 1 Ref vs Sample - 2 Ref – 1 Ref - 2 Sample – 1 Sample - 2 vs

Topics Platforms for gene expression profiling Breast cancer signatures From cell-based models to cancer classifiers

61 years IDC Postmenopausal N - pT = 0.9 cm Grade 2 ER et PgR - HER2 - FA(E)C x 6 % Choices of 40 experts worldwide AUCUNCMFx6ACx4TAMAUTRE SHOULD ONE TREAT A SMALL (<1CM) ENDOCRINE UNRESPONSIVE TUMOR ?

WHO CAN BE SPARED THERAPY? WHICH THERAPY WILL WORK BEST? Prognostic factors neededPredictive factors needed THERAPY DECISION-MAKING FOR EARLY BREAST CANCER

Clinical Outcome ER- ER+ PNAS vol 98, no 19, , 2001 The “Intrinsic” Breast Cancer Signatures

PNAS vol 100, no 18, , 2003 ER- ER+ grade Clinical Outcome Confirmatory Study

Amsterdam’s Signature 312 patients 70 genes Rotterdam’s Signature 286 patients 76 genes Discovery of «poor prognosis signatures» for distant relapses

78 tumor samples 70-gene poor prognosis signature

Marc J Van de Vijver et al., NEJM, 347, 25, 2002 High RiskLow Risk 70-gene expression signature outperforms clinicopathological criteria

Lancet, 2005, 365, tumor samples

G3 G2 G1 Histologic Grade GG1 GG2 GG3 Genomic Grade Sotiriou et al., JNCI 2006 Poor inter observer reproducibility G2: difficult treatment decision making, under- or over-treatment likely Findings consistent across multiple data sets and microarray platforms More objective assessment Easier treatment decision-making High proportion of genes involved in cell proliferation !

Identify genes correlated with grade 1 vs grade 3 Grade 1Grade 3 Grade 1Grade 2Grade 3 Analyze on validation set (n = 125) ‏ Definition and validation of the Genomic Grade

Sorlie et al. PNAS 2001 Sotiriou et al. PNAS 2003 Van de Vijver et al. NEJM 2002 Central Pathology Review! Consistent Distribution of GG in Different Populations and Microarrays Platforms

GENE EXPRESSION SIGNATURE = POWERFUL PROGNOSTIC TOOL Highest priority = Transfer from bench to bedside HOW ?

Validation study… TRANSLATING MOLECULAR KNOWLEDGE INTO EARLY BREAST CANCER MANAGEMENT

THERAPY DECISION-MAKING FOR EARLY BREAST CANCER WHO CAN BE SPARED THERAPY? WHICH THERAPY WILL WORK BEST? Prognostic factors needed Predictive factors needed

Topics Platforms for gene expression profiling Breast cancer signatures From cell-based models to cancer classifiers

The Invasive Growth biological program Proliferation Differentiation, cell polarity, tubulogenesis Scattering and migration Survival and protection against apoptosis

MET SHH SMO PTCH1 GLI AFP CK19 ALB  -AT TO MLP-29 liver stem/progenitor cells activate the invasive growth program in response to HGF Hedgehog pathway Liver lineage Liver differentiation -3+3 MLP29 / liver log2 ratio CTRL HGF 6h HGF 16h Day 1 Day 2 Day 4

Induced at 1h HGF/CTRL 1h 6h 24h EGF/CTRL 1h 6h 24h Induced at 6h Induced at 24h Suppressed at 24h HGF/CTRL 1h 6h 24h EGF/CTRL 1h 6h 24h Suppr. at 1h Suppressed at 6h Suppressed at 24h HGF/CTRL 1h 6h 24h EGF/CTRL 1h 6h 24h The Invasive Growth Transcriptional Program

Total NKI Breast cancer Dataset (311 samples - Agilent) ‏ Rotterdam Breast cancer Dataset (286 samples - Affymetrix) ‏ Statistical analysis Kaplan-Meier COX proportional hazard IG genes ranked by their individual performance (SNR over 1000 bootstraps) ‏ Number of genes in the classifier optimized and definition of the nearest mean classifier (NMC) ‏ Classifier construction and in silico validation using breast cancer microarray datasets

The Nearest Mean Classifier AVG Z Z3Z2Z1 AVG Y Y3Y2Y1 AVG X X3X2X1 Class A Sample 3 Sample 2 Sample 1 AVG X X6X5X4 AVG Z Z6Z5Z4 AVG Y Y6Y5Y4 Class B Sample 6 Sample 5 Sample 4 Gene Z Gene Y Gene X Training Group ATraining Group B

The Nearest Mean Classifier AVG Z Z3Z2Z1 AVG Y Y3Y2Y1 AVG X X3X2X1 Good Progn Class Sampl e 3 Sampl e 2 Sampl e 1 AVG X X6X5X4 AVG Z Z6Z5Z4 AVG Y Y6Y5Y4 Poor Prog Class Sampl e 6 Sampl e 5 Sampl e 4 Gene Z Gene Y Gene X Zs Ys Xs Test sample Gen eZ Gen eY Gen eX Group AGroup B Pearson correlation -> classification

Invasive growth genes classify breast cancer samples by their metastatic propensity

Validation on the Rotterdam dataset (286 breast samples, Wang et all., Lancet, 2005) ‏ Cox’s proportional hazards model IG 49 genes Cumulative Survival Time to relapse or last follow-up (months) ‏ NKI 49 genes Cumulative Survival Time to relapse or last follow-up (months) ‏ Poor prognosis Good prognosis Legend: 0 = Good prognosis samples 1 = Poor prognosis samples

Breast cancer expression profiling: towards an integrated approach to personalized therapy

Acknowledgments IRCC Laboratory of Functional Oncogenomics Tommaso Renzulli Claudio Isella Daniela Cantarella Barbara Martinoglio Roberta Porporato IRCC Gynaecological Oncology Daniela Cimino Luca Fuso Prof. Michele De Bortoli Prof. Piero Sismondi